Netflix (NASDAQ: NFLX) shares have been moving in an uptrend last several months, and according to technical analysis, there is no risk of the bear market for now. Citigroup raised its price target on Netflix to $580, and the focus of investors is on Q4 results that will be released on Jan. 19. Fundamental analysis: The focus of investors is on Netflix Q4 results Netflix shares have weakened more than 7% since the beginning of 2021 year, and the risk of additional declines is not over yet. Many analysts agree that the US stock market could enter a correction phase that could add further pressure on Netflix shares. Netflix usage showed signs of slowing down in North America, and average monthly visitors fell in the U.S./Canada to 57.9M in December. Despite this, Citigroup raised its price target on Netflix to $580 from $450 as the company continue to dominate on both original TV series and acquired TV series. It is also important to say that the analyst firm Cowen raised its price target on Netflix to $650 from $625 on optimism about the company’s fiscal fourth quarter. Netflix will report Q4 results on Jan. 19, and the market expects
Novocure (NASDAQ: NVCR) announced today that William Doyle, the company’s Executive Chairman, and Dr. Uri Weinberg, the company’s Chief Science Officer, will participate in the 2020 Wells Fargo Virtual Healthcare Conference on September 9, 2020. Mr. Doyle and Dr. Weinberg will take part in a fireside chat at 8:40 a.m. EDT. Mr. Doyle and Dr. Weinberg will also participate in one-on-one meetings with investors throughout the day.
A live webcast of the presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event.
Novocure’s corporate presentation is updated periodically, and the current presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations. NovoCure has used, and intends to continue to use, its investor relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, gastric cancer and glioblastoma.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate,” "estimate,” "expect,” "project,” "intend,” "plan,” "believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2020 and its Quarterly Report on Form 10-Q filed on April 30, 2020 with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200904005154/en/
Chainlink (LINK) price recorded losses of over 21% in December but it has already managed to erase these losses in the first three days of trading in January. Fundamental analysis: Utilization on Matic apps Chainlink published a new report on how its oracles can be utilized in Matic Defi applications. The article also covers how Chainlink’s price feeds can be used to help applications get access to tamper-proof and premium data, which is resistant to flash loan attacks and other oracle exploits. Are you looking for fast-news, hot-tips and market analysis? Sign-up for the Invezz newsletter, today. Matic Network offers a powerful platform that is expected to boost mass adoption when it comes to DeFi applications. After its launch earlier this year, the network’s robust infrastructure helped it become a popular layer 2 solution. Moreover, Chainlink also gained significant exposure as the number one choice oracle network for decentralized finance protocols. Its price feeds represent the top quality in-production solution for DeFi protocols that prevent exploits and attacks. Developers who want to use Chainlink oracles and price feeds on the Matic Network are required to link their MetaMask wallet to the Matic Mumbai testnet. This way, developers are also able